• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Immatics N.V.

    5/13/25 7:05:24 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    6-K 1 6k-_q12025.htm 6-K 6-K

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

    May 13, 2025

    Commission File Number: 001-39363

    IMMATICS N.V.

    Paul-Ehrlich-Straße 15

    72076 Tübingen, Federal Republic of Germany

    (Address of Principal Executive Office)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F ☐

     


     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

    On May 13, 2025, Immatics N.V. (the “Company”) issued an interim report for the three-month period ended March 31, 2025, which is attached hereto as Exhibit 99.1, and issued a press release announcing the first quarter 2025 financial results and business update for the Company, which is attached hereto as Exhibit 99.2.

     

    INCORPORATION BY REFERENCE

    This Report on Form 6-K (other than Exhibit 99.2 hereto) including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Nos. 333-249408, 333-265820 and 333-280935) and the registration statements on Form F-3 (Registration Nos. 333-240260, 333-274218 and 333-286151) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

    EXHIBITS

     

     

    Exhibit

    Number

    Description

    99.1

    Immatics N.V. interim report for the three -month period ended March 31, 2025.

    99.2

    Press release dated May 13, 2025.

     

     

     

    2


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

     

    IMMATICS N.V.

    Date: May 13, 2025

    by:

    /s/ Harpreet Singh

    Harpreet Singh

    Chief Executive Officer

     

    3


    Get the next $IMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings